ClinicalTrials.gg
SuspendedNCT06479824Updated Oct 15, 2026

NHLBI and Cook Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty (TRAIPTA) Early Feasibility Study

An interventional study of TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty) in Tricuspid Valve Insufficiency, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Suspended at 2 sites in United States. Open to participants aged 21 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Not applicable, Interventional, and Treatment

How we know

Why this study was suspended
Enrollment has been put on hold by the sponsor to allow for further engineering evaluation and performance review of the investigational device, as well as reassessment of the underlying device reliability assumptions.
Updated Oct 15, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
21 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Tricuspid Valve Insufficiency with a site in United States — 27 open to participants now, 36 under way, none of them phase 3. Tricuspid Valve Insufficiency · United States.

Planned enrollment
22nd of 42
60 · median 63
Started
2025
with 3 others
No phase
39 of 60
18 open now
Registered
45th of 60
by date
Lead sponsor
2 of 60
National Heart, Lung, and Blood Institute (NHLBI)

Among the 60 studies in Tricuspid Valve Insufficiency with a site in United States, this one is the 22nd largest by planned enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2025, is one of 39 with no phase, and was the 45th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

27 of the 60 studies in Tricuspid Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 21 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Tricuspid Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

Background:

Tricuspid valve regurgitation is a disease where one of the heart valves leaks. The leak affects blood flow. People with this disease may feel breathless and lack energy; they may need to stay in the hospital when fluid builds up in the body. The tricuspid is the most difficult valve to repair with surgery. Researchers want to try a new procedure called trans-atrial intra-pericardial tricuspid annuloplasty (TRAIPTA).

Objective:

To test TRAIPTA in people with tricuspid valve regurgitation.

Eligibility:

Adults aged 21 years and over with tricuspid valve regurgitation. They must not be eligible for standard surgical repair.

Design:

Participants will be screened. They will have tests of their heart function; these will include blood tests, imaging scans, and a 6-minute walking test.

Participants will enter the hospital for at least 1 day. The TRAIPTA procedure will be done under sedation or general anesthesia. The TRAIPTA study device is a loop that will be placed around the heart like a belt. It acts like a lasso to reduce leakage of the heart valve. Doctors will put the device in place by inserting a wire through a vein in the leg; they will thread the device up to the heart through the vein. The wire will be removed, but the TRAIPTA device will remain in place.

Participants will have follow-up visits 4 times in 1 year after the procedure. These visits will include physical exams, blood tests, imaging scans, and other tests of heart function.

Researchers will contact participants or their doctors for heart test results for another 4 years....

Read the detailed description

Study Description:

Functional tricuspid valve regurgitation is common, has high morbidity and mortality, and has no good treatments. We developed a new transcatheter treatment for this orphan disease called TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty). In TRAIPTA, catheter tools cross the wall of the heart to enter the pericardial space surrounding the heart, encircle the heart around the atrioventricular groove, and apply tension to reshape and narrow the heart to help the leaky tricuspid valve to function better. After placing the belt, a closure device is deployed to close the puncture in the right atrial appendage.

This is the first human test of the TRAIPTA technique. It is offered to patients who are suffering from clinically significant tricuspid valve regurgitation and who have no other good treatment options.

Objectives:

The objectives of this study are to test whether TRAIPTA is feasible, safe, favorably remodels tricuspid annular geometry, and reduces severity of functional tricuspid valve regurgitation.

Primary Safety Endpoint:

The primary endpoint is safety, measured as a composite of freedom from major adverse cardiovascular events (MACE) assessed at 30 days after the TRAIPTA procedure, including all of the following:

  • All-cause Mortality
  • Stroke (disabling and non-disabling)
  • Device-related pulmonary thromboembolism (symptomatic)
  • TRAIPTA-related coronary compression requiring coronary revascularization or post-procedure relief of TRAIPTAcompression
  • Pericardial tamponade. Note that insertion of a pericardial drain and pericardial effusion requiring drainage is an expected part of the TRAIPTA procedure, and does not contribute to the primary safety endpoint.
  • Major cardiac structural related complications including cardiac surgery related to the device.
  • Major access site and vascular complications
  • Acute kidney injury requiring new renal replacement therapy.
  • Bleeding (major or worse) according to MVARC

Secondary (Performance) Endpoints:

The performance endpoints are secondary, and are assessed at the timepoints indicated.

  • Technical success (measured at exit from cath lab). All the following must be present:

    • Absence of procedural mortality; and
    • Successful access, delivery, and retrieval of the TRAIPTA Delivery System; and
    • Successful deployment and correct positioning of the TRAIPTA annuloplasty belt; and
    • Freedom from emergency surgery or reintervention related to the TRIAPTA or access procedure.
  • Device success (measured at 30 days). All of the following must be present:

    • Absence of procedural mortality or stroke; and
    • Proper placement and positioning of the TRAIPTA annuloplasty belt; and
    • Freedom from unplanned surgical or interventional procedures related to the device or access procedure; and
    • Safety of the TRAIPTA annuloplasty belt, including:

      • No evidence of structural or functional device failure
      • No specific device-related technical failure issues and complications
    • Reduction of TR by at least one degree without significant tricuspid valve stenosis.
03

Conditions studied

  • Tricuspid Valve Insufficiency

Keywords

  • Tricuspid Valve Regurgitation
  • Transcatheter
  • Circumferential Compressive Implant
04

Who can participate

Ages eligible
21 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults >= 21 years
  • Severe tricuspid valve regurgitation with intact tricuspid leaflets, due to annular dilation, leaflet tethering, etc.
  • class III or IV congestive heart failure (symptomatic tricuspid regurgitation)
  • Cardiac size suitable for available TRAIPTA study devices according to NHLBI Core Lab analysis of cardiac CTA indicating a TRAIPTA extracardiac perimeter of 25-40cm.
  • Concordance of the study central clinical eligibility committee
  • Consents to participate, in writing, and willing to comply with all study procedures for the duration of the study

Exclusion criteria

EXCLUSION CRITERIA:

  • Prior cardiac surgery, which may preclude pericardial access, or known pericardial adhesions
  • Prior coronary artery stent in the atrioventricular groove
  • Severe mitral valve regurgitation assessed by echo
  • Left ventricular systolic dysfunction, \< 0.30
  • Right atrial pacemaker lead if it might preclude trans-atrial access for TRAIPTA
  • Eligible for commercially-available transcatheter tricuspid valve replacement
  • Eligible for commercially-available tricuspid edge-to-edge repair (TTEER). Recurrent or persistent symptomatic tricuspid regurgitation despite TTEER is not excluded.
  • Having transcatheter heart valve implants at risk of compression by TRAIPTA based on anatomic location on pre-procedure CT
  • Severe pulmonary artery hypertension, pulmonary artery systolic pressure >=60 mm Hg
  • Severe baseline renal excretory dysfunction, \<30mL/min/1.73m\^2 unless on renal replacement therapy
  • Evidence of thrombus in left atrial appendage on baseline CTA
  • Known to study device materials (for example, nickel)
  • Acute coronary syndrome, myocardial infarction, or percutaneous coronary intervention within 30 days
  • Requiring other structural heart intervention or coronary revascularization procedure in next 3 months
  • Pregnancy or intent to become pregnant prior to completion of all 12-month protocol follow-up procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment

    TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty)

    Device: TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty)

Interventions

  • DeviceTRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty)

    In TRAIPTA, catheter tools cross the wall of the heart to enter the pericardial space surrounding the heart, encircle the heart around the atrioventricular groove, and apply tension to reshape and narrow the heart to help the leaky tricuspid valve to function better. After placing the belt, a closure device is deployed to close the puncture in the right atrial appendage.

06

What researchers measure

Primary outcomes

  1. Safety of TRAIPTA procedure

    Safety is measured as a composite of freedom from major adverse cardiovascular events (MACE) assessed at 30 days after the TRAIPTA procedure, including all of the following:-All-cause Mortality-Stroke (disabling and non-disabling)-Device-related pulmonary thromboembolism (symptomatic)-TRAIPTA-related coronary compression requiring coronary revascularization or post-procedure relief of TRAIPTA-compression-Pericardial tamponade. Note that insertion of a pericardial drain and pericardial effusion requiring drainage is an expected part of the TRAIPTA procedure, and does not contribute to the primary safety endpoint.-Major cardiac structural related complications including cardiac surgery related to the device.-Major access site and vascular complications-Acute kidney injury requiring new renal replacement therapy.-Bleeding (major or worse) according to MVARC

    Time frame: 30 days

07

Study locations

2 sites
  • Emory University
    Atlanta, Georgia 30308, United States
  • St. Francis Hospital and Heart Center
    Roslyn, New York 11576, United States
08

References and documents

Individual participant data

Plan to share: Yes — IPD that underline results in a publication will be shared. Medical images will not be shared because of intrinsic inability to protect confidentiality with reasonable effort.

Supporting information: Study protocol

Time frame: Data will be made available by the end of the project or protocol or at the time of associated publication.

Access criteria: BioData Catalyst is supported by NHLBI and access to data is controlled by the NHLBI Data Access Committee (DAC) utilizing the database of Genotypes and Phenotypes (dbGaP) permissions infrastructure. In order to access controlled-access data in BioData Catalyst, an investigator must have an approved Data Access Request (DAR) in dbGaP.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2025 (actual). Primary completion is estimated for Oct 2027, 25 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Oct 2027, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jun 28, 2024
StartActual
Aug 19, 2025
Primary completionEst.
Oct 1, 2027was Oct 2026
CompletionEst.
Sep 1, 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Oct 1, 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Oct 1, 2026→Oct 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06479824
Responsible party
Sponsor
First posted
Jun 28, 2024
Start date
Aug 19, 2025
Primary completion
Oct 1, 2027 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Robert J Lederman, M.D.
principal investigator · National Heart, Lung, and Blood Institute (NHLBI)

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion